Ribo completed the enrollment of the first patient into the Chinese phase II clinical trial on ASOISIS449884 Injection

Suzhou Ribo Life Science Co., Ltd. today announced that its phase II clinical trial of ISIS449884 Injection, an ASO for the treatment of type 2 diabetes, had completed the enrollment of the first patient and the subject was successfully administered the first dose of study drug.

Ribo was selected as one of 2019 "Most Innovative Pharmaceutical Companies in Asia" by Clarivate Analytics

Ribo's clinical application for new oligonucleotide therapeutics in the treatment of type 2 diabetes got approved

Recently, the Center for Drug Evaluation, National Medical Products Administration completed the technical review on the application for a clinical trial of a new oligonucleotide therapeutics for the treatment of type 2 diabetes submitted by Suzhou Ribo Life Science Co., Ltd., and issued the Notice for Clinical Trial.

The clinical application of Suzhou Ribo for new drug for treatment of type 2 diabetes got accepted by CDE

Recently, Center for Drug Evaluation, National Medical Products Administration officially accepted the clinical trial application of imported drug ISIS449884 Injection submitted by Suzhou Ribo Life Science Co. Ltd.,. This product belongs to Class 1 innovative drug not marketed in China or abroad, and the proposed indication is type 2 diabetes.

Phase II/III study of optic neuroprotective oligonucleotide therapeutics QPI-1007 completed dosing of the first subject in China

Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. announced that in the global pivotal II/III study QRK207 of its innovative siRNA drug QPI-1007 for optic nerve protection, the investigational product has been administered to the first subject by Professor Wang Ningli's team at Beijing Tongren Hospital, Capital Medical University, China.